- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 88,220 | 30.05.24 10:03:26 | +0,200 | +0,23% | 88,000 | 88,060 | 88,230 | 88,020 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 882,200 | 30.05.24 08:12:02 | -12,800 | -1,43% | 880,800 | 891,600 | 882,200 | 895,000 |
